BSR & BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists

doi:10.1093/rheumatology/kel216a

Rheumatology Advance Access first published online on August 28, 2006
This version published online on September 27, 2006
Rheumatology, doi:10.1093/rheumatology/kel216a

This Article

	FREE Full Text (PDF)
	Full Guidelines
	All Versions of this Article: 47/6/924 most recent kel216av3 kel216av2 kel216av1
	Alert me when this article is cited
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Personal Archive
	Download to citation manager
	Request Permissions
	Disclaimer

Google Scholar

	Articles by Chakravarty, K.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Chakravarty, K.

Social Bookmarking

	What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received February 19, 2006
Accepted May 12, 2006

Guidelines

BSR & BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists

K. Chakravarty ¹ ^*, H. McDonald ², T. Pullar ³, A. Taggart ⁴, R. Chalmers ⁵, S. Oliver ⁶, J. Mooney ⁷, M. Somerville ⁸, and A. Bosworth ⁹, on behalf of the British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group in association with the British Association of Dermatologists (BAD)

¹ Harold Wood Hospital, BHR Trust, Romford
² Gubbins Lane Surgery, Harold Wood
³ Nine Wells Hospital, Dundee
⁴ Musgrave Park Hospital, Belfast
⁵ Manchester Royal Infirmary, Manchester
⁶ Royal College of Nursing Rheumatology Forum and Litchdon Health Centre, Barnstaple
⁷ Norfolk & Norwich University Hospital and University of East Anglia
⁸ Norfolk & Norwich Hospital, Norwich
⁹ National Rheumatoid Arthritis Society

^* To whom correspondence should be addressed.
K. Chakravarty, E-mail: Kuntal.Chakravarty{at}bhrhospitals.nhs.uk

This article has no Abstract. Keywords: DMARD; Guideline; Multidisciplinary; Multiprofessional.

There are corrections to be made to this paper, a new version will be published shortly.

CiteULike

Connotea

Del.icio.us What's this?

This article has been cited by other articles:

K. Lindsay, A. Gough, A. Layton, and S. Fraser
Comment on: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long term, high cumulative dose methotrexate therapy: reply
Rheumatology, November 1, 2009; 48(11): 1465 - 1465.
[Full Text] [PDF]

B. Chikura, S. Lane, and J. K. Dawson
Clinical expression of leflunomide-induced pneumonitis
Rheumatology, September 1, 2009; 48(9): 1065 - 1068.
[Abstract] [Full Text] [PDF]

A. McLean-Tooke, C. Aldridge, S. Waugh, G. P. Spickett, and L. Kay
Methotrexate, rheumatoid arthritis and infection risk--what is the evidence?
Rheumatology, August 1, 2009; 48(8): 867 - 871.
[Abstract] [Full Text] [PDF]

A. K. Bhalla and M. Samaranayaka
Comment on: BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists
Rheumatology, October 1, 2008; 47(10): 1591 - 1591.
[Full Text] [PDF]

K. Chakravarty
Comment on: BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists: reply
Rheumatology, October 1, 2008; 47(10): 1591 - 1591.
[Full Text] [PDF]

P. Jobanputra
BSR DMARD monitoring guidelines: sulfasalazine
Rheumatology, October 1, 2008; 47(10): 1587 - 1588.
[Full Text] [PDF]

				B. Chikura, S. Lane, and J. K. Dawson Clinical expression of leflunomide-induced pneumonitis Rheumatology, September 1, 2009; 48(9): 1065 - 1068. [Abstract] [Full Text] [PDF]

				A. McLean-Tooke, C. Aldridge, S. Waugh, G. P. Spickett, and L. Kay Methotrexate, rheumatoid arthritis and infection risk--what is the evidence? Rheumatology, August 1, 2009; 48(8): 867 - 871. [Abstract] [Full Text] [PDF]

				A. K. Bhalla and M. Samaranayaka Comment on: BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists Rheumatology, October 1, 2008; 47(10): 1591 - 1591. [Full Text] [PDF]

				K. Chakravarty Comment on: BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists: reply Rheumatology, October 1, 2008; 47(10): 1591 - 1591. [Full Text] [PDF]

				P. Jobanputra BSR DMARD monitoring guidelines: sulfasalazine Rheumatology, October 1, 2008; 47(10): 1587 - 1588. [Full Text] [PDF]